Physician profile
Randy C Fullerton
NPI 1356325237
$8,700.18
in general payments reported to CMS, 2019-2025
31 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,396 · 2020: $1,569 · 2021: $1,874 · 2022: $1,393 · 2023: $958 · 2024: $1,389 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,429.46 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,429.11 | 2019-2024 | Xifaxan |
| Novo Nordisk INC | $868.38 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $844.65 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $515.99 | 2020-2024 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $365.66 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.22 | 2019-2024 | Jardiance |
| Amgen INC. | $291.82 | 2019-2025 | Repatha, Otezla |
| Abbvie INC. | $282.97 | 2019-2024 | |
| Astellas Pharma US INC | $275.39 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $243.45 | 2019-2023 | Xarelto |
| Abbott Laboratories | $188.65 | 2021-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $178.39 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $173.25 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $170.14 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $156.50 | 2020 | |
| Amarin Pharma, INC. | $141.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $122.11 | 2019-2021 | |
| Esperion Therapeutics, INC. | $118.62 | 2021 | |
| Nestle Healthcare Nutrition INC. | $118.16 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $77.41 | 2020-2021 | |
| Exact Sciences Corporation | $74.68 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $61.19 | 2019-2020 | |
| Ibsa Pharma INC. | $57.47 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $50.51 | 2022-2023 | Quviviq |
| Eisai INC. | $34.29 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $21.34 | 2024 | Voquezna |
| Bausch Health US, LLC | $17.77 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.87 | 2019 | |
| Vistapharm, INC. | $16.73 | 2021 | |
| Valeritas, INC. | $15.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Fullerton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.